Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?

Publikováno v: Bone Marrow Transplantation, 50(11), 1411-1415. Nature Publishing Group
Bone Marrow Transplantation, 50, 1411-1415. Nature Publishing Group

Allogeneic hematopoietic transplantation is increasingly used in patients aged 55 years or more with AML. The question of whether outcomes can be improved with an allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d29ac3b4b609666c450ffac5396c07e4
https://doi.org/10.1038/bmt.2015.180

Zobrazit plný text záznamu

Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria

Autor: J.Y. Cahn, Richard Kelly, Thierry Lamy, Gabrielle Meyers, Maria Teresa Uranga, Ilene C. Weitz, Anita J. Hill, J. A. García Vela, Miguel A. Sanz, Peter Hillmen, Beth Severino

Publikováno v: Internal Medicine Journal. 43:298-307

Background Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired, clonal haemopoietic stem cell disorder that causes chronic intravascular haemolysis, increases the risk of thrombosis and results in significant patient morbidity and mortalit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::469612be8227ff439fde0e95c86eb51d
https://doi.org/10.1111/j.1445-5994.2012.02924.x

Zobrazit plný text záznamu

Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results

Publikováno v: H., G, H., K, A., D, S., S, S., Z, J.J., K, P., B, H., S, F., S, A., F, D., H-M, H., P, F., S, K., D, K., B, A., R, F., B, G., E, J.C., I, D., R, L., R, J.Y., C, C., H, D., R, P., M, N., M, C., B, F., C, P., J, G., B, F., P, B., A, J., S, G., B, X., S, J., X, P., Z, Z., X, T., B, T., B, Z., S, M., G, A., R, M., F, T., L, R., S & R., M 2016, ' Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results ', Haematologica, vol. 101, pp. 564 . < http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L615559578 http://sfx.aub.aau.dk/sfxaub?sid=EMBASE&issn=15928721&id=doi:&atitle=Development+of+an+MF+patient+reported+outcome+%28PRO%29+tool+for+FDA+qualification%3A+Comprehensive+li >
Haematologica, 101. Ferrata Storti Foundation

Background: Myelofibrosis (MF) is recognized for its debilitating constitutional symptoms, splenomegaly, profound cytopenias and inflammatory state. Current MPN PROs (MF-SAF, MPN-SAF and MPN-10) have proven sensitive for symptom detection. Formal FDA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ec56bdd330f96427d54a20493bc7ccda
https://research.vumc.nl/en/publications/e387e992-15eb-4a36-9779-458a6e8ea43b

Zobrazit plný text záznamu

Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

Autor: Colette Raffoux, Mohamad Mohty, R. Tabrizi, J.Y. Cahn, Ibrahim Yakoub-Agha, J. H. Bourhis, Yosr Hicheri, Norbert Ifrah, Mauricette Michallet, Agnès Buzyn, Nathalie Dhedin, Myriam Labopin, Marie-Lorraine Balere, Didier Blaise, Gérard Socié, Helene Esperou, Noel Milpied

Publikováno v: Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2010, 24 (11), pp.1867-74. ⟨10.1038/leu.2010.200⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2010, 24 (11), pp.1867-74. 〈10.1038/leu.2010.200〉

International audience; This retrospective report assessed the impact of rabbit antithymocyte globulins (ATG), incorporated within a standard myeloablative conditioning regimen prior to allogeneic stem cell transplantation (allo-SCT) using human leuk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2051648fc8115d4e338da5ef892233f1
https://doi.org/10.1038/leu.2010.200

Zobrazit plný text záznamu

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

Publikováno v: Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2015, 29 (7), pp.1496-1501. ⟨10.1038/leu.2015.37⟩

International audience; Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the only a curative treatment in patients with higher risk myelodysplastic syndrome (MDS), although demethylating agents (DMA) have been reported to impro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e3f5ff5c0a456f20eb23cec31446ac
https://hal.umontpellier.fr/hal-02123041

Zobrazit plný text záznamu

Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation

Autor: Christophe Ferrand, Pierre Rohrlich, Pierre Tiberghien, Fabrice Larosa, Philippe Saas, K. Ledu, J.Y. Cahn, Philippe Helias, Eric Robinet, Claude-Eric Bulabois, E. Deconinck, Marmier C

Publikováno v: Bone Marrow Transplantation. 35:859-868

Peripheral blood stem cell transplantation after reduced-intensity conditioning (RIC-PBSCT) regimen is an alternative to conventional regimens with less immediate toxicity. Since immune recovery is of crucial importance for the control of infections,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291a1563c10242772333e83d86428fe4
https://doi.org/10.1038/sj.bmt.1704889

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání